Suven Life Sciences Performance
- Today's Low
- ₹255
- Today's High
- ₹272
- 52 Week Low
- ₹124
- 52 Week High
- ₹300
- Open Price₹258
- Previous Close₹260
- Volume1,458,412
- 50 DMA₹235.25
- 100 DMA₹211.43
- 200 DMA₹196.32
Suven Life Sciences Chart
Investment Returns
- Over 1 Month -0.49%
- Over 3 Month + 100.1%
- Over 6 Month + 56.84%
- Over 1 Year + 18%
Smart Investing Starts Here Start SIP with Suven Life Sciences for Steady Growth!
Suven Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -25.6
- PEG Ratio
- 0.4
- Market Cap Cr
- 7,073
- P/B Ratio
- 12
- Average True Range
- 16.62
- EPS
- 0
- Dividend Yield
- 0
- MACD Signal
- 11.22
- RSI
- 57.68
- MFI
- 32.62
Latest Stock News Updates
Clinical-stage biotech will present three posters highlighting Phase 2 results and Phase 3 plans for narcolepsy treatment.
- Business Line
- 1 week 2 days ago
Conducted entirely in the United States, the randomised, double-blind, placebo-controlled trial aims to evaluate the safety and efficacy of Ropanicant across 195 patients at 35 sites over six weeks.
- Business Line
- 6 months 1 week ago
Healthcare Services company Suven Life Sciences announced Q2FY26 results Revenue: Rs 46.97 million against Rs 66.09 million during Q2FY25. PAT: Rs -773.10 million against Rs -496.44 million during Q2FY25. EPS: Rs -3.48 for Q2FY26. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026. SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026. SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026. Result PDF
- Trendlyne
- 7 months 1 week ago
Suven Life Sciences Financials
Suven Life Sciences Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹259.50
- 50 Day
- ₹235.20
- 100 Day
- ₹211.40
- 200 Day
- ₹196.30
Resistance and Support
- R3 292.07
- R2 281.83
- R1 275.02
- S1 257.97
- S2 247.73
- S3 240.92
Suven Life Sciences Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-13 | Audited Results | |
| 2026-01-29 | Quarterly Results | |
| 2025-11-11 | Quarterly Results | |
| 2025-08-13 | Quarterly Results | |
| 2025-05-13 | Audited Results & Preferential issue |
About Suven Life Sciences
- NSE Symbol
- SUVEN
- BSE Symbol
- 530239
- Chairman & Managing Director
- Mr. Venkateswarlu Jasti
- ISIN
- INE495B01038
Similar Stocks to Suven Life Sciences
Popular Stocks
Suven Life Sciences FAQs
Suven Life Sciences share price is ₹268 As on 22 June, 2026 | 07:51
The Market Cap of Suven Life Sciences is ₹7073 Cr As on 22 June, 2026 | 07:51
The P/E ratio of Suven Life Sciences is -25.6 As on 22 June, 2026 | 07:51
The PB ratio of Suven Life Sciences is 12 As on 22 June, 2026 | 07:51
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.